Addressing Performance, Scalability, and Regulatory Challenges to Accelerate Cell Therapy Manufacturing: To date, the FDA has approved 36 cell and gene therapy products (1). In the past decade, new cell therapy modalities such as chimeric antigen receptor T-cell (CAR-T) immunotherapies have emerged as promising treatments especially for many types of cancers. There are now six FDA approved commercially available CAR-T products (2) and the development of cell therapies is continuing to gather pac
Saved in:
| Published in | Biopharm international Vol. 37; no. 7; p. 14 |
|---|---|
| Main Authors | , , |
| Format | Magazine Article |
| Language | English |
| Published |
Intellisphere, LLC
01.07.2024
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Audience | Trade |
|---|---|
| Author | Ladi, Rukmini Cashen, Paul Deckers, Susanne |
| Author_xml | – sequence: 1 fullname: Cashen, Paul – sequence: 2 fullname: Deckers, Susanne – sequence: 3 fullname: Ladi, Rukmini |
| BookMark | eNqVkk1PGzEQhheJSnyU_zBHIiUom4QUuK0CqD1UQnQP3NBgT7yuvPbKH4H93_yAjs1He-3BsqyZ9513Hvmo2rfO0n51WJ-vFrN6vX44qI5C-D2f1xfLy9Xh3msjpacQtFVwR37rfI9W0BR-CTT4pI2O4xTQSrgnlQxG50fYdGgMWUUBooNGCDLkMRJsyBhoO34MI_xEm7YoYvJsfgWtA8k9U4gdwe11Ax0GwGHwbkcSlmsQWZwnKbKUu4oL12USMcBpPTmDH7bIBwwRJAmU7Gfp-U37IemdRM6tOV5IogOeIzrdk9eC_aNmf_AkaOBloJ0V7emmuZ-1E9B9n6x7c8oGHe4IiLWKQ7IRx-l1oRU9YezJcjQKAwnNTEZggMAER4jjwHK3BZF5-nBWuBAgH-ueIeiXQuGTgHA9j3m3wR1qxm8Yac71D4XFpDDKFCTtyLghZyiD_jLIyTVv7Xhbm0paBwpzkdmJr9WXLZpAJ-_3cTW9vWk332cKDT0-Jd6vfImgVReDwhTCY3MxX11-W6zO6-V_tv8BS43eKA |
| ContentType | Magazine Article |
| Copyright | COPYRIGHT 2024 Intellisphere, LLC |
| Copyright_xml | – notice: COPYRIGHT 2024 Intellisphere, LLC |
| DBID | N95 XI7 |
| DatabaseName | Gale Business: Insights Business Insights: Essentials |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| ExternalDocumentID | A804972451 |
| GroupedDBID | --- 04C 0R~ 23N 3V. 53G 5GY 6J9 7RV 7WY 883 88I 8AF 8AO 8FE 8FH 8FI 8FJ 8FL 8G5 8R4 8R5 96U ABUBX ABUWG ACGOD ACMJI ACPRK ADBBV ADFRT AENEX AFAZI AFKRA AGFXM AHHXF AKVCP ALIPV ALMA_UNASSIGNED_HOLDINGS AMDGZ AZQEC BAAKF BAW BAWUL BBNVY BENPR BEZIV BHPHI BKEYQ BKOMP BMSDO BNT BPHCQ BVXVI CCPQU DIK DWQXO E3Z EBD EBO EBS EBU EIHBH EJD EX3 F8P FAC FRNLG FYUFA GNUQQ GROUPED_ABI_INFORM_COMPLETE GUQSH HCIFZ HZ~ IAO IGG INH INR IOF ITC ITG ITH K60 K6~ LGEZI LK8 LOTEE M0F M2O M2P M2Q M7P ML0 N95 NADUK NAPCQ NXXTH NYMDV O9- OK1 P6G PQBIZ PQBZA PQQKQ PRG PROAC Q2X TAF TH9 TR2 U5U UKHRP UNMZH USXSC WOW XI7 |
| ID | FETCH-gale_businessinsightsgauss_A8049724513 |
| ISSN | 1542-166X |
| IngestDate | Tue Oct 08 15:48:55 EDT 2024 |
| IsPeerReviewed | false |
| IsScholarly | false |
| Issue | 7 |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-gale_businessinsightsgauss_A8049724513 |
| ParticipantIDs | gale_businessinsightsgauss_A804972451 |
| PublicationCentury | 2000 |
| PublicationDate | 20240701 |
| PublicationDateYYYYMMDD | 2024-07-01 |
| PublicationDate_xml | – month: 07 year: 2024 text: 20240701 day: 01 |
| PublicationDecade | 2020 |
| PublicationTitle | Biopharm international |
| PublicationYear | 2024 |
| Publisher | Intellisphere, LLC |
| Publisher_xml | – name: Intellisphere, LLC |
| SSID | ssj0018394 |
| Score | 2.514252 |
| SourceID | gale |
| SourceType | Aggregation Database |
| StartPage | 14 |
| SubjectTerms | Antigens Drug approval Gene therapy Genes Immunotherapy T cells |
| Title | Addressing Performance, Scalability, and Regulatory Challenges to Accelerate Cell Therapy Manufacturing: To date, the FDA has approved 36 cell and gene therapy products (1). In the past decade, new cell therapy modalities such as chimeric antigen receptor T-cell (CAR-T) immunotherapies have emerged as promising treatments especially for many types of cancers. There are now six FDA approved commercially available CAR-T products (2) and the development of cell therapies is continuing to gather pac |
| Volume | 37 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1Lb9pAEMfdhF566ltNX5pDEwXZoGAbML1Rkiip0gghV-IWOfYSrAaMsnZU-mX7JfoBOjO79pqqB9qLhSy8u8zsD-9j5r-W9WGQdHBqjJ237x_NWr4nuq1BQLky9C73_CCedSh3-Mtl7-yr_3nane7s_qxFLRX5dTv-8de8kv_xKt5Dv1KW7D94tioUb-Bn9C9e0cN43crHwyThMFac7Y9NAgAvaKLplQL3uozPnKhT52lPfVSeoMLyDsM4xncPSUbYI8FHebLQAEXGFJT3wImMvAyf2bQ-QAXScPX0eGjPI6lkye9x4Or1bNoH4NqwzcLOdUkrJSurVKH23UEb_5ZUjlYkczsRsRb_xSG-KqF8cJElNE_A2bwti3hOh-LE81SF_2OXICVRG_-yxQp_lh22-Fnalh5OWiGtd6SU_aJzzKiQOZ21JDjjNKHCsGHYz9VRGTrgXtqCsk_RebcqlnVBERG0Us1BLzFZ-E622UrCprg5yiaU6Xe2R2ULdPeCDrPiYqL7KL3lHDVu2YY9XGpnGcaamBAurszYglqfSs4sSJcFtzizb3j4jlaMN_bm02xFguQsBVKt9prNJqkTcupBoceCwmtkFadlgi0uooQDPibFN5Khqa8SuX4VUaxXDpS-qySpCnWA98Wo_tbz3VZHHSlZvRaVFo_Gv197x6mk303p8ul5f_OmklQOcP7Zd32SONjtB37Devjp5HI8qbb5cHTOYR9l_XpcVBvhhU-sx6XUOgwVaE-tHbF8Zh2Mlbj72oHQ5CpKBw5gbGTf188f_DI0Qo1GB2osOoCeBkMiGBIhz8CQCESirnANGyR-hDAD8oAD6H3AXgdIIZQ9D7weUL_hmohC0DBB2evgsNNsw_mSHycCQRHoAPKnni0fMfwB8QdYT8kfaP6g5A8Uf3DIfbwJf7AHxB5o9qigij0w7IFhD9CAQOwBswfZDEr22C4CkD1A9gDZYytUFqizBxV7wO2qWcFtso3ICjXuuCJjA2p5ir-64o78pLhD28UvLOf0JBydtahDXekTffEiac1T3kSFlFemf3ovrcYyW4pXFkTdyHPjrn8t_J6fBP7gaNbxRILzpijwhBjsWftbFfl6y--9sR4ZYN9ajfyuEO9wopNfv9e4_AbDo3gH |
| link.rule.ids | 780,784 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Addressing+Performance%2C+Scalability%2C+and+Regulatory+Challenges+to+Accelerate+Cell+Therapy+Manufacturing%3A+To+date%2C+the+FDA+has+approved+36+cell+and+gene+therapy+products+%281%29.+In+the+past+decade%2C+new+cell+therapy+modalities+such+as+chimeric+antigen+receptor+T-cell+%28CAR-T%29+immunotherapies+have+emerged+as+promising+treatments+especially+for+many+types+of+cancers.+There+are+now+six+FDA+approved+commercially+available+CAR-T+products+%282%29+and+the+development+of+cell+therapies+is+continuing+to+gather+pac&rft.jtitle=Biopharm+international&rft.au=Cashen%2C+Paul&rft.au=Deckers%2C+Susanne&rft.au=Ladi%2C+Rukmini&rft.date=2024-07-01&rft.pub=Intellisphere%2C+LLC&rft.issn=1542-166X&rft.volume=37&rft.issue=7&rft.spage=14&rft.externalDBID=XI7&rft.externalDocID=A804972451 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1542-166X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1542-166X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1542-166X&client=summon |